New hope for liver cancer patients with damaged livers?
NCT ID NCT05622071
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called tislelizumab in 50 people with advanced liver cancer who also have moderate liver damage (Child-Pugh B). The goal was to see if the drug could shrink tumors. Tislelizumab works by helping the immune system attack cancer cells. The study took place in France and included people who may or may not have had prior treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA BY BCLC STAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHRU Strasbourg
Strasbourg, France
-
CHU Angers
Angers, France
-
CHU Beaujon
Clichy, France
-
CHU La Croix Rousse
Lyon, France
-
CHU Saint Eloi
Montpellier, France
-
Centre Eugene Marquis
Rennes, France
-
Hôpital Avicenne
Bobigny, France
-
Hôpital Michallon
Grenoble, France
-
Hôpital Saint Joseph
Marseille, France
-
Institut Paoli Calmette
Marseille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.